Family Site

The contents provided by this page are intended only for Australian healthcare professionals.
Please leave this site if you are not an Australian healthcare professional.

About Remsima® How Remsima® works

About Remsima®

Remsima® (infliximab), is the world’s first biosimilar monoclonal antibody(mAb) for the treatment of autoimmune diseases developed by Celltrion. Remsima® is developed into dual formulation of intravenous and subcutaneous.

Remsima® IV was approved by international drug regulatory agencies across about 110 countries including the Remsima®SC is the world's first SC formulation of infliximab and has been approved approved by the Therapeutic Goods Administration (TGA) and European Medicines Agency(EMA). In Australia, Remsima®SC is available as pre-filled pen and pre-filled syringe. The availability of Infliximab in Australia as dual formulation (IV and Remsima®SC )provides a tailored treatment based on the individual needs of patients.

Subcutaneous injection

  • Remsima® 120mg solution for injection in pre-filled pen

  • Remsima® 120mg solution for injection in
    pre-filled syringe with needle guard

  • References

    1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.

    2.  Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. ” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271

    Abbreviations

    SC, subcutaneous; AS, ankylosing spondylitis; CD, Crohn's disease; EMA, European Medicines Agency; PsA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; UC, ulcerative colitis